UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval

The Lancet. Psychiatry, 2019-12, Vol.6 (12), p.977-979

Turner, Erick H

2019

Volltextzugriff (PDF)

Does Publication Bias Inflate the Apparent Efficacy of Psychological Treatment for Major Depressive Disorder? A Systematic Review and Meta-Analysis of US National Institutes of Health-Funded Trials

PloS one, 2015-09, Vol.10 (9), p.e0137864-e0137864

2015

Volltextzugriff (PDF)

Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database

PLoS medicine, 2012-03, Vol.9 (3), p.e1001189

2012

Volltextzugriff (PDF)

Reporting of Positive Results in Randomized Controlled Trials of Mindfulness-Based Mental Health Interventions

PloS one, 2016-04, Vol.11 (4), p.e0153220-e0153220

2016

Volltextzugriff (PDF)

Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials

PLoS medicine, 2022-01, Vol.19 (1), p.e1003886-e1003886

2022

Volltextzugriff (PDF)

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

The New England journal of medicine, 2008-01, Vol.358 (3), p.252-260

2008

Volltextzugriff (PDF)

An open science pathway for drug marketing authorization—Registered drug approval

PLoS medicine, 2021-08, Vol.18 (8), p.e1003726-e1003726

2021

Volltextzugriff (PDF)

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

The Lancet (British edition), 2018-04, Vol.391 (10128), p.1357-1366

2018

Volltextzugriff (PDF)

Unpublished trials of alprazolam XR and their influence on its apparent efficacy for panic disorder

Psychological medicine, 2024-04, Vol.54 (5), p.1026-1033

2024

Volltextzugriff (PDF)

WHAT IS THE THRESHOLD FOR A CLINICALLY RELEVANT EFFECT? THE CASE OF MAJOR DEPRESSIVE DISORDERS

Depression and anxiety, 2014-05, Vol.31 (5), p.374-378

2014

Volltextzugriff (PDF)

Publication Bias, with a Focus on Psychiatry: Causes and Solutions

CNS drugs, 2013-06, Vol.27 (6), p.457-468

Turner, Erick H.

2013

Volltextzugriff (PDF)

Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder

Cochrane database of systematic reviews, 2021-09, Vol.9 (11), p.CD011612

2021

Volltextzugriff (PDF)

ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis

BMJ (Online), 2023-11, p.e076754

2023

Volltextzugriff (PDF)

Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis

BMJ open, 2016-07, Vol.6 (7), p.e010919-e010919

2016

Volltextzugriff (PDF)

Approval of esketamine for treatment-resistant depression – Author's reply

The Lancet. Psychiatry, 2020-03, Vol.7 (3), p.236-236

Turner, Erick H

2020

Volltextzugriff (PDF)

Rethinking recommendations for screening for depression in primary care

Canadian Medical Association journal (CMAJ), 2012-03, Vol.184 (4), p.413-418

2012

Volltextzugriff (PDF)

From the FDA, we still hear mostly thunderous silence

BMJ (Online), 2015-07, Vol.351, p.h3763

Turner, Erick H

2015

Volltextzugriff (PDF)

Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials

Psychological medicine, 2019-09, Vol.49 (12), p.2020-2026

2019

Volltextzugriff (PDF)

Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses

JAMA psychiatry (Chicago, Ill.), 2015-05, Vol.72 (5), p.500

2015

Volltextzugriff (PDF)

Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments

JAMA : the journal of the American Medical Association, 2011-03, Vol.305 (10), p.1008

2011

Volltextzugriff (PDF)

Influence of baseline severity on antidepressant efficacy for anxiety disorders: Meta-analysis and meta-regression

British journal of psychiatry, 2016-06, Vol.208 (6), p.515-521

2016

Volltextzugriff (PDF)

Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study

BMJ open, 2020-05, Vol.10 (5), p.e035633-e035633

2020

Volltextzugriff (PDF)

Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis

European neuropsychopharmacology, 2016-11, Vol.26 (11), p.1752-1759

2016

Volltextzugriff (PDF)

Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009

Systematic reviews, 2020-04, Vol.9 (1), p.77-77, Article 77

2020

Volltextzugriff (PDF)

Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications

BMJ, 2009-08, Vol.339 (7719), p.b2981-b2981

International edition, 2009

Volltextzugriff (PDF)

1 – 25 von 161

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(146)
Mit Volltextzugriff
(128)

Publikationsform

Sprache

Englisch
(161)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(106)
Life Sciences & Biomedicine
(94)
Humans
(83)
Psychiatry
(41)
Female
(36)
Biological And Medical Sciences
(33)
Adult
(32)
Male
(30)
Medical Sciences
(29)
Clinical Trials
(27)
Psychology. Psychoanalysis. Psychiatry
(27)
Middle Aged
(26)
General & Internal Medicine
(24)
Medicine, General & Internal
(24)
Psychopathology. Psychiatry
(22)
United States
(22)
Depression
(21)
Antidepressants
(17)
Antidepressive Agents - Therapeutic Use
(17)
Neurosciences & Neurology
(17)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Esketamine for treatment-resistant depression: seven concerns about efficacy and FDA approval

Does Publication Bias Inflate the Apparent Efficacy of Psychological Treatment for Major Depressive Disorder? A Systematic Review and Meta-Analysis of US National Institutes of Health-Funded Trials

Publication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration database

Reporting of Positive Results in Randomized Controlled Trials of Mindfulness-Based Mental Health Interventions

Selective publication of antidepressant trials and its influence on apparent efficacy: Updated comparisons and meta-analyses of newer versus older trials

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

An open science pathway for drug marketing authorization—Registered drug approval

Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis

Unpublished trials of alprazolam XR and their influence on its apparent efficacy for panic disorder

WHAT IS THE THRESHOLD FOR A CLINICALLY RELEVANT EFFECT? THE CASE OF MAJOR DEPRESSIVE DISORDERS

Publication Bias, with a Focus on Psychiatry: Causes and Solutions

Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder

ROB-ME: a tool for assessing risk of bias due to missing evidence in systematic reviews with meta-analysis

Comparative efficacy and acceptability of first-generation and second-generation antidepressants in the acute treatment of major depression: protocol for a network meta-analysis

Approval of esketamine for treatment-resistant depression – Author's reply

Rethinking recommendations for screening for depression in primary care

From the FDA, we still hear mostly thunderous silence

Hiding negative trials by pooling them: a secondary analysis of pooled-trials publication bias in FDA-registered antidepressant trials

Reporting Bias in Clinical Trials Investigating the Efficacy of Second-Generation Antidepressants in the Treatment of Anxiety Disorders: A Report of 2 Meta-analyses

Reporting of conflicts of interest in meta-analyses of trials of pharmacological treatments

Influence of baseline severity on antidepressant efficacy for anxiety disorders: Meta-analysis and meta-regression

Reporting of drug trial funding sources and author financial conflicts of interest in Cochrane and non-Cochrane meta-analyses: a cross-sectional study

Bias in the reporting of harms in clinical trials of second-generation antidepressants for depression and anxiety: A meta-analysis

Reporting of financial conflicts of interest in meta-analyses of drug trials published in high-impact medical journals: comparison of results from 2017 to 2018 and 2009

Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications

Suchergebnisse filtern